Pulsed Field Ablation Catheter Patents: Top Companies & Trends 2026
Pulsed field ablation catheter patents: who leads, and where the field is still open
Concentrated at the top. The five largest assignees together hold 35.4% of all 5,726 records in scope, and the ranked ten hold 46.4% — leaving a long tail of single- and few-filing entrants below. Filings rose from 270 in 2017 to a peak of 465 in 2023. The most recent complete comparison, 2021 to 2024, shows a -16% change (336 to 281); 2025 and 2026 figures are still incomplete because publication trails filing by roughly 18 months, so the apparent drop-off in the newest years should not be read as the field slowing.
- 1BOSTON SCIENTIFIC SCIMED INC12.5%
- 2BIOSENSE WEBSTER (ISRAEL) LTD8.4%
- 3ST JUDE MEDICAL CARDILOGY DIV INC6.0%
- 4MEDTRONIC ARDIAN LUXEMBOURG SARL5.5%
- 5VIRGINIA TECH INTELLECTUAL PROPERTIES INC3.0%
See the full pulsed field ablation catheters analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on pulsed field ablation catheter patents
Who holds the most patents on pulsed field ablation catheters?
One assignee leads the ranked list with 716 records, well ahead of the fifth-place filer at 170 and the tenth at 99. The top five assignees together account for 35.4% of all 5,726 records in scope, and the top ten account for 46.4%. That still leaves more than half the field spread across a long tail of smaller filers, including research universities and mid-size device companies, so a single leader does not equate to a closed field.
Is pulsed field ablation catheter patent filing still growing?
Filings rose steadily from 270 in 2017 to a peak of 465 in 2023. The most recent reliable comparison, using complete-year data from 2021 to 2024, shows a -16% change (336 to 281), suggesting a plateau after the peak rather than sustained growth. Counts for 2025 and 2026 appear lower still, but that reflects publication lag of roughly 18 months rather than an actual drop in filing activity, so those years should not yet be read as a decline.
What technology areas do these patents actually cover?
78.1% of the 5,726 records carry an A61B classification for surgical and diagnostic devices, confirming this is primarily a catheter and procedure landscape. A61N electrotherapy claims, covering waveform and energy delivery specific to pulsed field methods, appear in 30.0% of records. Smaller shares touch body-fluid devices, cell-level electroporation biology, implants, pharmacological adjuncts and measurement methods, and because records can carry multiple classes these shares add up to more than 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Pulsed Field Ablation Catheters covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.